Mobile Software As A Medical Device (SaMD) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Mobile Software As A Medical Device (SaMD) Market Trends and Insights

Clinical Adoption of AI-Assisted Diagnosis and Monitoring

Clinical AI software is moving from limited pilots into broader hospital operations. Aidoc raised USD 150 million in Series E funding in April 2026, taking its total funding above USD 500 million, and reported that its systems analyze more than 60 million patient cases annually across nearly 2,000 hospitals. This scale supports the shift toward enterprise platforms covering triage, diagnosis, and treatment decisions across specialties. Aidoc also received an FDA Breakthrough Device Designation for First Read in June 2026, its second designation in less than 1 year. Hospitals are replacing disconnected point tools with platforms that offer common governance and clearer accountability, favoring suppliers with broad clinical coverage, reliable oversight, and proven routine-care performance.

Expansion of Smartphone-Enabled Remote Patient Monitoring

Smartphone-enabled remote patient monitoring is moving beyond passive data capture into reimbursed clinical care. CMS reimbursement for AI-enhanced ECG analysis became effective in January 2025, and Viz.ai reported profitability in its healthcare business by the end of 2025. The 2024 merger of Biofourmis and CopilotIQ combined pre-surgical, acute, post-acute, and chronic-care capabilities on 1 platform. Biofourmis reported a 70% reduction in 30-day readmissions, a 21-hour earlier indication of clinical deterioration, and up to 38% lower cost of care. These results help payers and providers assess outcome improvement and cost control, while improving market access for vendors with comparable real-world evidence and workflow integration.

Rising Chronic Disease Management Requirements

Chronic disease management continues to drive demand in the mobile software as a medical device market for tools that support patients between clinical visits. Noncommunicable diseases caused 74% of deaths worldwide, with cardiovascular conditions and diabetes among the key use cases for remote monitoring and digital therapeutic programs. Japan's PMDA approved Apple's Hypertension Notification Feature as a home-use diagnostic program in November 2025, while Germany's DiGA pathway offered a reimbursable route for digital health applications across cardiology, diabetes care, and mental health. Cleared products for hypertension, diabetes, and cardiac rhythm monitoring have stronger support for sustained adoption than products without a clear care or payment pathway.

Cloud Interoperability and Virtual Care Integration

In the mobile software as a medical device market, cloud delivery enables providers to access software across care settings without maintaining separate infrastructure at each location. It supports software updates, centralized administration, and integration with telehealth platforms and electronic health records. Providers need systems that manage access controls and protect patient data, while hybrid designs can keep sensitive data local and use cloud resources for analytics and broader coordination. This approach is becoming more important in countries where national rules restrict cross-border health data movement, creating opportunities for suppliers that combine interoperability with practical data storage and processing controls.

Clinical Validation and Evidence-Generation Requirements

Clinical evidence requirements are becoming more stringent for software that supports diagnosis or treatment. The FDA's January 2025 draft guidance described a total product life cycle approach for AI-enabled device software functions, covering performance monitoring, data quality, bias assessment, and clinician-AI interaction. Varying standards of care across providers and countries make study design complex. These requirements can favor companies with health-system partners, established quality systems, and clear post-market monitoring pathways.

Cybersecurity, Privacy, and Cross-Border Health-Data Restrictions

Connected clinical software must protect patient information throughout its use and maintenance. The FDA issued final cybersecurity guidance in June 2025 covering quality system considerations and premarket submission content for medical devices. Developers must address software bills of materials, security testing, vulnerability management, and timely disclosure processes. Differing data and software rules across the United States, Europe, and Asia-Pacific can increase development costs and slow deployment in the mobile software as a medical device market, especially for smaller suppliers entering multiple regions.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Enterprise Platforms Lead While Monitoring Software Expands

Clinical Decision Support Software held 33.22% of the product category in 2025, making it the largest product category. Health systems use these products for triage, diagnosis, and treatment planning across radiology, cardiology, and emergency medicine. Enterprise buyers prefer platforms that support multiple use cases over separate products for each condition, as common platforms simplify governance, data management, and staff training.

Tempus AI received FDA 510(k) clearance for its updated Tempus Pixel cardiac imaging platform in September 2025. The clearance followed its acquisition of Arterys and showed how regulatory scope and acquired capabilities can strengthen an enterprise offering. Remote Patient Monitoring Software is forecast to grow at a CAGR of 20.93% from 2026 to 2031, the fastest rate among product types.

By Device Type: Wearables Hold the Largest Position While Smartphones Broaden Access

Wearable Devices accounted for 36.23% of the device category in 2025, the largest position among device types. Smartwatches, wearable ECG devices, blood-pressure monitors, and smart rings provide continuous or frequent physiological data. Their clinical role has expanded as more devices receive regulatory clearance for defined health functions.

Smartphones and Tablets are forecast to grow at a CAGR of 19.67% from 2026 to 2031, making them the fastest-growing device channel. They support prescription apps, remote communication, and camera-based measurement without requiring an additional device. This capability can extend care to rural and underserved settings where dedicated equipment is less available.

By Deployment: Cloud-Based Solutions Lead While Hybrid Models Address Data Rules

Cloud-Based deployment held 59.34% of the mobile software as a medical device market size in 2025. Providers use cloud systems to reduce local hardware requirements and distribute software updates faster. Subscription models also improve spending predictability for hospitals and clinics.

Hybrid Cloud is forecast to grow at a CAGR of 18.35% from 2026 to 2031, the fastest rate among deployment models. It allows providers to keep sensitive patient data in a local environment while using cloud functions for analytics or coordination. This design can help vendors address data residency requirements in China, India, and the European Union.

By Application: Screening Leads While Cardiovascular Uses Gain Speed

Screening and Early Detection accounted for 32.88% of the mobile software as a medical device market size in 2025. Health systems value tools that identify risk or possible disease before symptoms require more intensive treatment. These programs can reach larger populations and may have a lower cost per screen than later-stage interventions.

Cardiovascular Screening is forecast to grow at a CAGR of 19.78% from 2026 to 2031, the highest rate among applications. Cardiac monitoring benefits from improving AI models, validated wearables, and reimbursement for AI-enhanced ECG analysis. A 2025 study in Frontiers in Cardiovascular Medicine found that a smartphone-guided secondary prevention application reduced systolic blood pressure in patients with chronic coronary syndrome and insufficient blood pressure control.

By End User: Hospitals and Clinics Lead While Home Care Accelerates

Hospitals and Clinics held 45.89% of end-user demand in 2025, the largest share in the mobile software as a medical device market. They have procurement processes, clinical governance structures, and information technology teams that support integration with electronic health records and imaging systems. Large health systems are increasingly standardizing on a single vendor across multiple sites instead of funding department-level pilots.

Home-Care Settings are forecast to grow at a CAGR of 20.45% from 2026 to 2031, the fastest rate among end users. Hospital-at-home programs and payer-funded chronic disease contracts are moving continuous monitoring into lower-acuity settings. Home use can reduce travel and allow clinicians to follow patients between visits. The reported Biofourmis results on readmissions, earlier deterioration detection, and cost of care give providers a basis to assess these programs. Ambulatory and specialist centers are also adopting tools for outpatient cardiology, oncology, and neurology. Insurers, occupational health providers, and direct-to-consumer platforms may invest in software when it supports better outcomes or lower total care costs.

Geography Analysis

North America held 38.55% of global demand in 2025, supported by a mature FDA pathway for regulated software and expanding reimbursement for AI-enabled diagnostics and remote monitoring. Category III CPT codes for AI-enabled ECG analysis took effect in January 2025. Large integrated health systems deployed enterprise platforms across multiple facilities, generating real-world datasets for software monitoring and improvement. Canada began assessing AI-enabled software through its health technology assessment process, while Mexico developed frameworks for digital medical software.

Asia-Pacific is forecast to grow at a CAGR of 19.56% from 2026 to 2031, the fastest regional rate in the mobile software as a medical device market. Aging populations, chronic disease needs, expanding digital infrastructure, and developing regulatory pathways supported demand in the mobile software as a medical device market. Japan's PMDA approved 581 SaMD products as of March 2025 under its DASH for SaMD policy, while the PMDA approval of Apple's hypertension feature provided a recent example of home-use regulation. China and India formalized requirements for AI medical software through their national regulatory systems, while Qure.ai reported deployments in more than 100 countries and 39 million patient scans processed.

Europe represented a significant share in 2025, with Germany, the United Kingdom, and France supporting demand through established reimbursement and regulatory processes. Germany's DiGA framework offered a prescribed and reimbursed route for qualifying digital health applications, while the region's compliance requirements made evidence and data protection critical for market entry. The Middle East and Africa remained earlier-stage areas, but hardware-light software addressed gaps in specialist access.